Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMRA-323511 in Healthy Elderly and Adults With Agitation Associated With Alzheimer's Disease
NCT06546995Phase 1Completed
- Sponsor
- Neumora Therapeutics, Inc.
- Start
- Jul 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NMRA-323511 in Alzheimer's disease (AD) (4 arms), sponsored by Neumora Therapeutics, Inc. Primary endpoints: Treatment Emergent Adverse Events at 53 days and Cohen-Mansfield Agitation Inventory Total Score at 8 weeks. Started Jul 2024; status: completed.
02
Drugs
NMRA-323511
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06546995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06546995.